Peptron Inc
Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, … Read more
Peptron Inc (087010) - Net Assets
Latest net assets as of September 2025: ₩146.33 Billion KRW
Based on the latest financial reports, Peptron Inc (087010) has net assets worth ₩146.33 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩183.74 Billion) and total liabilities (₩37.42 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩146.33 Billion |
| % of Total Assets | 79.64% |
| Annual Growth Rate | 35.66% |
| 5-Year Change | 96.68% |
| 10-Year Change | 780.61% |
| Growth Volatility | 121.17 |
Peptron Inc - Net Assets Trend (2014–2024)
This chart illustrates how Peptron Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Peptron Inc (2014–2024)
The table below shows the annual net assets of Peptron Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩151.71 Billion | +319.93% |
| 2023-12-31 | ₩36.13 Billion | -31.98% |
| 2022-12-31 | ₩53.11 Billion | -14.73% |
| 2021-12-31 | ₩62.28 Billion | -19.25% |
| 2020-12-31 | ₩77.13 Billion | +174.63% |
| 2019-12-31 | ₩28.09 Billion | -37.72% |
| 2018-12-31 | ₩45.10 Billion | -7.86% |
| 2017-12-31 | ₩48.95 Billion | -8.01% |
| 2016-12-31 | ₩53.21 Billion | +208.86% |
| 2015-12-31 | ₩17.23 Billion | +139.90% |
| 2014-12-31 | ₩7.18 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Peptron Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 271919764000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩165.25 Billion | 108.92% |
| Total Equity | ₩151.71 Billion | 100.00% |
Peptron Inc Competitors by Market Cap
The table below lists competitors of Peptron Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Fastprint Circuit Tech Co Ltd
SHE:002436
|
$3.92 Billion |
|
ISS A/S
OTCGREY:ISFFF
|
$3.92 Billion |
|
Tsinghuatongfang Co Ltd
SHG:600100
|
$3.92 Billion |
|
Beijing Teamsun Technology Co Ltd
SHG:600410
|
$3.93 Billion |
|
Huadian Power International Corp Ltd Class A
SHG:600027
|
$3.92 Billion |
|
RioCan Real Estate Investment Trust
TO:REI-UN
|
$3.92 Billion |
|
Doosan Pref Shs
KO:000155
|
$3.91 Billion |
|
EnBW Energie Baden-Württemberg AG
XETRA:EBK
|
$3.91 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Peptron Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 36,127,013,420 to 151,708,566,270, a change of 115,581,552,850 (319.9%).
- Net loss of 22,033,671,490 reduced equity.
- Share repurchases of 139,067,928,000 reduced equity.
- New share issuances of 139,067,928,000 increased equity.
- Other factors increased equity by 137,615,224,340.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-22.03 Billion | -14.52% |
| Share Repurchases | ₩139.07 Billion | -91.67% |
| Share Issuances | ₩139.07 Billion | +91.67% |
| Other Changes | ₩137.62 Billion | +90.71% |
| Total Change | ₩- | 319.93% |
Book Value vs Market Value Analysis
This analysis compares Peptron Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 47.61x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 76.87x to 47.61x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4045.86 | ₩311000.00 | x |
| 2017-12-31 | ₩3137.08 | ₩311000.00 | x |
| 2018-12-31 | ₩2798.09 | ₩311000.00 | x |
| 2019-12-31 | ₩1742.57 | ₩311000.00 | x |
| 2020-12-31 | ₩3739.46 | ₩311000.00 | x |
| 2021-12-31 | ₩3019.50 | ₩311000.00 | x |
| 2022-12-31 | ₩2574.77 | ₩311000.00 | x |
| 2023-12-31 | ₩1757.76 | ₩311000.00 | x |
| 2024-12-31 | ₩6532.58 | ₩311000.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Peptron Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -14.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -699.00%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.11x
- Recent ROE (-14.52%) is above the historical average (-25.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -47.03% | -122.66% | 0.21x | 1.79x | ₩-3.69 Billion |
| 2015 | -15.85% | -97.09% | 0.13x | 1.26x | ₩-4.45 Billion |
| 2016 | -6.00% | -101.93% | 0.05x | 1.09x | ₩-8.51 Billion |
| 2017 | -9.04% | -137.68% | 0.06x | 1.08x | ₩-9.32 Billion |
| 2018 | -8.26% | -96.48% | 0.05x | 1.59x | ₩-8.24 Billion |
| 2019 | -63.08% | -983.70% | 0.03x | 2.17x | ₩-20.53 Billion |
| 2020 | -23.83% | -589.03% | 0.03x | 1.53x | ₩-26.10 Billion |
| 2021 | -24.15% | -227.07% | 0.09x | 1.25x | ₩-21.27 Billion |
| 2022 | -28.36% | -259.08% | 0.09x | 1.29x | ₩-20.37 Billion |
| 2023 | -44.07% | -476.43% | 0.06x | 1.45x | ₩-19.53 Billion |
| 2024 | -14.52% | -699.00% | 0.02x | 1.11x | ₩-37.20 Billion |
Industry Comparison
This section compares Peptron Inc's net assets metrics with peer companies in the Biotechnology & Medical Research industry.
Industry Context
- Industry: Biotechnology & Medical Research
- Average net assets among peers: $68,646,864,222
- Average return on equity (ROE) among peers: -3.26%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Peptron Inc (087010) | ₩146.33 Billion | -47.03% | 0.26x | $3.92 Billion |
| Macrogen Inc (038290) | $118.01 Billion | 2.24% | 0.52x | $99.40 Million |
| Panagene Inc (046210) | $30.94 Billion | 0.00% | 0.90x | $29.96 Million |
| Cell Biotech Co. Ltd (049960) | $52.36 Billion | 19.87% | 0.10x | $43.10 Million |
| Bioneer Corporation (064550) | $26.11 Billion | -55.21% | 1.44x | $175.97 Million |
| MEDIPOST Co. Ltd (078160) | $143.31 Billion | -3.74% | 0.25x | $192.41 Million |
| Biotoxtech Co. Ltd (086040) | $41.14 Billion | 17.29% | 1.21x | $23.35 Million |